Hasegawa Gen, Nakagawa Noriharu, Ueda Yoshimichi, Yamazaki Masahide
Department of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan.
Department of Pathology, Keiju Medical Center, Nanao, Ishikawa, Japan.
Leuk Res Rep. 2025 Jan 14;23:100500. doi: 10.1016/j.lrr.2025.100500. eCollection 2025.
Brentuximab vedotin (BV) has demonstrated efficacy against CD30 peripheral T-cell lymphoma (PTCL). We herein report a case of CD30 peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) therapy for anaplastic large cell lymphoma (ALCL) and responded to retreatment with BV monotherapy. This case suggests that CD30 PTCL emerging shortly after BV-CHP therapy may respond to retreatment with BV monotherapy, even if the phenotype differs from the initial diagnosis.
本妥昔单抗（BV）已显示出对CD30外周T细胞淋巴瘤（PTCL）有效。我们在此报告一例未另行指定的CD30外周T细胞淋巴瘤（PTCL-NOS）病例，该病例在完成针对间变性大细胞淋巴瘤（ALCL）的BV、环磷酰胺、多柔比星和泼尼松（BV-CHP）治疗后1个月出现，并对BV单药再治疗有反应。该病例表明，BV-CHP治疗后不久出现的CD30 PTCL可能对BV单药再治疗有反应，即使其表型与初始诊断不同。
